Core Decompression With or Without Cement Packing for ONFH
NCT ID: NCT04233125
Last Updated: 2020-01-18
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE1/PHASE2
37 participants
INTERVENTIONAL
1997-01-01
2008-01-01
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Randomized Clinical Trial for the Treatment of Osteonecrosis of the Femoral Head
NCT01892514
The Treatment of Initial Stage of Hip Osteonecrosis: the Core Decompression
NCT04210440
Treatment of Osteonecrosis of the Femoral Head by Bone Marrow Transplantation
NCT00821470
Hyperbaric Oxygen Therapy Versus Core Decompression Augmented With Bone Substitute in Pre Collapse of Avascular Necrosis of Femoral Head
NCT04657653
Controlled Study of Stage 3 Osteonecrosis Treatment by Bone Marrow
NCT01544712
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Consecutive symptomatic patients aged \>14 years with Association Research Circulation Osseous (ARCO) Stage I and II ONFH diagnosed using MRI and radiographic imaging were enrolled in this study.
Exclusion criteria were pre-existing collapse, sub-chondral fracture or degenerative changes of the hip.
After obtaining informed written consent, patients are asked to complete the Harris Hip Score (HHS), Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC), and a health status questionnaire Short Form-36 (SF-36).
The femoral heads enrolled into the study are randomized using a computer-generated card draw system to one of following: core decompression (CD) or core decompression with PMMA cement packing (CD + PMMA).
Allocation concealment was practiced with the use of opaque envelopes. Patients with bilateral involvement who had been randomized to one treatment modality for one femoral head were automatically selected to receive the other treatment modality for the contralateral femoral head.
Blinding of either surgeon or patient is impossible.
The patients were followed up after surgery every 3-4 months for the first 2 years after which the patients were seen annually. Completed questionnaires and radiographs were obtained at each visit.
Statistical Analysis The date of index procedure (CD or CD + PMMA) was used as start date for the purpose of statistical analysis. Progression Free Survival was defined as the time to radiographic progression and Conversion Free Survival (CFS) as the time to a THA. In case of patients who did not have radiographic progression, the date of their last follow up or death was used for the analysis. The SAS software will be used for all the analyses. The Log rank and Gerhan-Wilcoxon tests were used to compare Kaplan-Meier survival curves for the time from the date of the index procedure to radiographic progression (subchondral collapse) or conversion to THA for separate groupings based on age at index procedure (\<40 , \>40 yrs), smoking (Y/N), location (central, medial, lateral), percent involvement (\<15% \[mild\], 15% to 30% \[moderate\], or \>30% \[severe\]), index of necrotic extent (\<40 or \>40), and modified index of necrotic extent (\<40 or \>40). Whenever factors were found to affect the survival curves mainly in the initial year the Gerhan-Wilcoxon test was used as the test of significance. The Kaplan-Meier curves were also compared for the main cohorts of CD vs. CD + PMMA. Cox proportional hazards regression was used to compare factors (age, smoking, location, percent involvement, index of necrotic extent, and modified index of necrotic extent) with regards to their ability to predict the time to progression or revision to THA. Mixed multilevel regression modeling was used to test for group differences in the change in self-rated health survey scores over time from baseline over the post-operative period. The hierarchical linear modeling approach has a number of advantages over traditional repeated measures approaches for modeling change over time, including allowance for missing data and for varying measurement times across subjects. Separate models were generated for SF-36, Harris Hip Score and WOMAC scores over two-year and over 5-year post-operative time periods.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Core Decompression (CD) Only
Participants in this group receive standard care
Core Decompression
Core Decompression
Added Polymethylmethacrylate (PMMA)
Participants in this group receive standard care with an additional treatment
Core Decompression
Core Decompression
PMMA augmentation
Polymethylmethacrylate (PMMA) augmentation
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Core Decompression
Core Decompression
PMMA augmentation
Polymethylmethacrylate (PMMA) augmentation
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
Exclusion Criteria
14 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
University of Minnesota
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
9604M11032
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.